Shares of this gene editing company are due to surge more than 45%, Citi says
Investors should pick up shares of biotech Prime Medicine as it regains the market's favor after a period of steady underperformance, according to Citi.
Investors should pick up shares of biotech Prime Medicine as it regains the market's favor after a period of steady underperformance, according to Citi.
